ATE527385T1 - Mit tumoren assoziierte genetische variationen - Google Patents

Mit tumoren assoziierte genetische variationen

Info

Publication number
ATE527385T1
ATE527385T1 AT07871494T AT07871494T ATE527385T1 AT E527385 T1 ATE527385 T1 AT E527385T1 AT 07871494 T AT07871494 T AT 07871494T AT 07871494 T AT07871494 T AT 07871494T AT E527385 T1 ATE527385 T1 AT E527385T1
Authority
AT
Austria
Prior art keywords
tumors
variations associated
genetic variations
diagnosing
nucleotide
Prior art date
Application number
AT07871494T
Other languages
English (en)
Inventor
Somasekar Seshagiri
Brock Peters
Zhengyan Kan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE527385T1 publication Critical patent/ATE527385T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07871494T 2006-11-16 2007-11-15 Mit tumoren assoziierte genetische variationen ATE527385T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86610306P 2006-11-16 2006-11-16
US94881807P 2007-07-10 2007-07-10
PCT/US2007/084888 WO2008061213A2 (en) 2006-11-16 2007-11-15 Genetic variations associated with tumors

Publications (1)

Publication Number Publication Date
ATE527385T1 true ATE527385T1 (de) 2011-10-15

Family

ID=39402492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07871494T ATE527385T1 (de) 2006-11-16 2007-11-15 Mit tumoren assoziierte genetische variationen

Country Status (8)

Country Link
US (1) US20100092965A1 (de)
EP (1) EP2082064B1 (de)
JP (1) JP2010509922A (de)
AT (1) ATE527385T1 (de)
AU (1) AU2007319214B2 (de)
CA (1) CA2667851A1 (de)
ES (1) ES2374954T3 (de)
WO (1) WO2008061213A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
WO2010030865A2 (en) * 2008-09-11 2010-03-18 The Regents Of The University Of California Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor
KR101735125B1 (ko) 2008-11-12 2017-05-15 리젠메드 (케이만) 엘티디. 분리된 신장 세포 및 이의 용도
US8320346B2 (en) * 2009-09-25 2012-11-27 Intel Corporation Apparatus and methods for universal services interface networking
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12545960B2 (en) 2010-05-18 2026-02-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
BR112014012979A2 (pt) * 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20170044621A1 (en) * 2014-04-18 2017-02-16 Blueprint Medicines Corporation Met fusions
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CA2945962C (en) * 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
EP4217376A4 (de) 2020-09-24 2024-10-09 University of Massachusetts Für nf1 codierende aav-vektoren und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232370D1 (de) * 2001-06-14 2009-06-25 Univ California Mutationen in der mit der resistenz gegenüber sti-
US20050266417A1 (en) * 2003-09-12 2005-12-01 Francis Barany Methods for identifying target nucleic acid molecules
EP1680011A4 (de) * 2003-10-02 2007-11-21 Univ South Florida Bestimmung des phänotyps von krebs und von präkanzerösem gewebe
US20060115827A1 (en) * 2004-07-01 2006-06-01 University Of Southern California Genetic markers for predicting disease and treatment outcome
WO2007109515A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of knockdown resistance polypeptide

Also Published As

Publication number Publication date
JP2010509922A (ja) 2010-04-02
WO2008061213A3 (en) 2008-12-18
AU2007319214A1 (en) 2008-05-22
ES2374954T3 (es) 2012-02-23
US20100092965A1 (en) 2010-04-15
WO2008061213A2 (en) 2008-05-22
EP2082064A2 (de) 2009-07-29
EP2082064B1 (de) 2011-10-05
AU2007319214B2 (en) 2014-04-17
CA2667851A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
BRPI0912927A2 (pt) "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
EP2318088A4 (de) Tragbare anordnungen, systeme und verfahren zur bereitstellung funktioneller oder therapeutischer neurostimulation
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
MX2009004522A (es) Variantes de suceptibilidad a cancer en chr8q24.21.
WO2009100188A3 (en) Methods for detection of corn event das-59132
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
BRPI0906237A2 (pt) manipulação de sistema de informação de célula e tempo especifico para entrega em utra evoluido.
DE602007003165D1 (de) Verfahren und Systeme zur Definition, Identifikation und Erfassung geometrischer Eigenschaften
ATE542903T1 (de) Luciferase-biosensoren für camp
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010062913A3 (en) Methods and systems for analysis of sequencing data
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
DK2024747T3 (da) Anvendelse af protein SATB2 som prognotisk markør for colerectal cancer
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
DK2179035T3 (da) Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2082064

Country of ref document: EP